Multinational pharmaceutical companies aim at China's pharmaceutical R & D


Release time:

2012-08-29

Even with a large number of high-quality R & D personnel, sufficient R & D funds and leading technology in the world, the market speed of new drugs in the United States has slowed down in recent years. Relevant data show that in 2006, the US Food and Drug Administration approved only 18 new drugs for listing, which is lower than the average level in the past six years. Correspondingly, many large pharmaceutical companies have accelerated the introduction of new R & D projects from all over the world. According to statistics, among many well-known multinational pharmaceutical companies, independent research and development projects account for only 1/3 of all research projects, and the rest of the projects are imported from outside.
IMS Health, a world-renowned medical information consulting company, reported that in 2006, U.S. pharmaceutical companies will have patent protection for prescription drugs worth $19 billion, and in 2007, patent protection for prescription drugs worth $10 billion will expire. Once patent protection lapses, generic drug companies then introduce low-priced corresponding generic drugs, and sales of patented drugs usually fall sharply.
Most importantly, it usually takes $1 billion to develop a new drug in Europe and the United States, 12 to 15 years, and the difficulty is increasing. At the end of 2006, Pfizer announced the suspension of clinical research on cholesterol-lowering drugs, and the company has invested $1 billion in this project. And on the other hand. It usually costs only 30 million to 80 million US dollars to obtain a global market development right for a new drug that has entered the clinical research stage from other drug research and development companies.
Zhou Mingdong said that, therefore, the introduction of mature projects for multinational pharmaceutical companies not only greatly shortens the development time of new drugs, reduces risks, but also saves development costs.
According to Dr. Liu Riting, Director of Business Development of the R & D Department of Shanghai Fosun Pharmaceutical Group Co., Ltd., many multinational companies try to obtain China's scientific research results that are only one step away from maturity through legal capital operation methods such as cooperation, acquisitions, and mergers. There are other strategic needs.
Liu Riting believes that some multinational pharmaceutical companies often use patent strategies to control the development of R & D, spend a lot of money to acquire Chinese inventions and patents, and then very skillfully shelve these projects, or delay the development of these projects, and let themselves The project on hand develops rapidly. The result is that some Chinese inventions and patents no longer receive any patent licensing fees, and more importantly, these multinational companies have strangled potential Chinese competitors in the cradle.